Role of homocysteine in the treatment of Parkinson's disease

References

• Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med.351(24), 2498–2508 (2004).
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov. Disord.21(3), 332–336 (2006).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson’s disease: implications for the early use of COMT inhibitors. Neurology55(11 Suppl. 4), S72–S77 (2000).
   PubMed Web of Science ®Google Scholar
• Agid Y. Levodopa: is toxicity a myth? Neurology50(4), 858–863 (1998).
   PubMed Web of Science ®Google Scholar
• Kann PH. Growth hormone in anti-aging medicine: a critical review. Aging Male6(4), 257–263 (2003).
   PubMedGoogle Scholar
• Lanfranco F, Gianotti L, Giordano R, Pellegrino M, Maccario M, Arvat E. Ageing, growth hormone and physical performance. J. Endocrinol. Invest.26(9), 861–872 (2003).
   PubMedGoogle Scholar
• Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-dopa and the catechol-O-methyltransferase inhibitor Ro 41- 0960 on sulfur amino acid metabolites in rats. Clin. Neuropharmacol.20(1), 55–66 (1997).
   PubMed Web of Science ®Google Scholar
• Müller T, Kuhn W, Przuntek H. Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J. Neural Transm. Gen. Sect.92(2–3), 187–195 (1993).
   PubMedGoogle Scholar
• Zhu BT. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr. Drug Metab.3(3), 321–349 (2002).
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s disease. Synapse43(3), 201–207 (2002).
   PubMed Web of Science ®Google Scholar
• Russ H, Müller T, Woitalla D, Rahbar A, Hahn J, Kuhn W. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch. Pharmacol.360(6), 719–720 (1999).
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Bremen D et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin. Neuropharmacol.29(2), 61–67 (2006).
   PubMed Web of Science ®Google Scholar
• Müller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opin. Pharmacother.7(13), 1715–1730 (2006).
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Muhlack S et al. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease. J. Neural Transm.114(11), 1457–1462 (2007).
   PubMed Web of Science ®Google Scholar
• Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin. Pharmacokinet.45(2), 109–136 (2006).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stocchi F. COMT inhibitors in Parkinson’s disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology62(1 Suppl. 1), S72–S81 (2004).
   Web of Science ®Google Scholar
• Smith LA, Jackson MJ, Al Barghouthy G et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Disord.20(3), 306–314 (2005).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch. Neurol.62(6), 905–910 (2005).
   PubMed Web of Science ®Google Scholar
• Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology62(1 Suppl. 1), S47–S55 (2004).
   PubMed Web of Science ®Google Scholar
• Nissinen E, Nissinen H, Larjonmaa H et al. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J. Neural Transm.112(9), 1213–1221 (2005).
   PubMed Web of Science ®Google Scholar
• Müller T, Kuhn W. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson’s disease patients. Eur. J. Clin. Pharmacol.62(6), 447–450 (2006).
   PubMedGoogle Scholar
• Brosnan JT, Jacobs RL, Stead LM, Brosnan ME. Methylation demand: a key determinant of homocysteine metabolism. Acta Biochim. Pol.51(2), 405–413 (2004).
   PubMed Web of Science ®Google Scholar
• Huang G, Dragan M, Freeman D, Wilson JX. Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons. Glia51(1), 47–55 (2005).
   PubMed Web of Science ®Google Scholar
• Kang SS. Treatment of hyperhomocyst(e)inemia: physiological basis. J. Nutr.126(4 Suppl.), 1273S–1275S (1996).
   Google Scholar
• Kuhn W, Hummel T, Woitalla D, Müller T. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology56(2), 281–282 (2001).
   PubMedGoogle Scholar
• Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology60(7), 1125–1129 (2003).
   PubMed Web of Science ®Google Scholar
• Nakaso K, Yasui K, Kowa H et al. Hypertrophy of IMC of carotid artery in Parkinson’s disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J. Neurol. Sci.207(1–2), 19–23 (2003).
   PubMed Web of Science ®Google Scholar
• Beal MF. Excitotoxicity and nitric oxide in Parkinson’s disease pathogenesis. Ann. Neurol.44(3 Suppl. 1), S110–S114 (1998).
   Web of Science ®Google Scholar
• Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet351(9095), 36–37 (1998).
   PubMed Web of Science ®Google Scholar
• Gerlach M, Blum-Degen D, Lan J, Riederer P. Nitric oxide in the pathogenesis of Parkinson’s disease. Adv. Neurol.80, 239–245 (1999).
   PubMedGoogle Scholar
• Stamler JS, Osborne JA, Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J. Clin. Invest.91(1), 308–318 (1993).
   PubMed Web of Science ®Google Scholar
• Lipton SA, Kim WK, Choi YB et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. USA94(11), 5923–5928 (1997).
   PubMed Web of Science ®Google Scholar
• Parsons RB, Waring RH, Ramsden DB, Williams AC. in vitro effect of the cysteine metabolites homocysteic acid, homocysteine and cysteic acid upon human neuronal cell lines. Neurotoxicology19(4–5), 599–603 (1998).
   PubMed Web of Science ®Google Scholar
• Cheng H, Gomes-Trolin C, Aquilonius SM et al. Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson’s disease. Exp. Neurol.145(2 Pt 1), 580–585 (1997).
   PubMed Web of Science ®Google Scholar
• Miller AL. The methionine-homocysteine cycle and its effects on cognitive diseases. Altern. Med. Rev.8(1), 7–19 (2003).
   PubMedGoogle Scholar
• Siniscalchi A, Mancuso F, Gallelli L, Ferreri IG, Biagio MN, De SG. Increase in plasma homocysteine levels induced by drug treatments in neurologic patients. Pharmacol. Res.52(5), 367–375 (2005).
   PubMed Web of Science ®Google Scholar
• Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer’s disease. J. Neurochem.67(3), 1328–1331 (1996).
   PubMed Web of Science ®Google Scholar
• Mulder C, Schoonenboom NS, Jansen EE et al. The transmethylation cycle in the brain of Alzheimer patients. Neurosci. Lett.386(2), 69–71 (2005).
   PubMedGoogle Scholar
• Fuso A, Seminara L, Cavallaro RA, D’Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and β-amyloid production. Mol. Cell Neurosci.28(1), 195–204 (2005).
   PubMed Web of Science ®Google Scholar
• Scarpa S, Fuso A, D’Anselmi F, Cavallaro RA. Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease? FEBS Lett.541(1–3), 145–148 (2003).
   PubMed Web of Science ®Google Scholar
• Selhub J. Folate, vitamin B12 and vitamin B6 and one carbon metabolism. J. Nutr. Health Aging6(1), 39–42 (2002).
   PubMedGoogle Scholar
• Selley ML. A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer’s disease. Neurobiol. Aging28(12), 1834–1839 (2007).
   PubMedGoogle Scholar
• Sontag E, Nunbhakdi-Craig V, Sontag JM et al. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J. Neurosci.27(11), 2751–2759 (2007).
   PubMed Web of Science ®Google Scholar
• Tchantchou F. Homocysteine metabolism and various consequences of folate deficiency. J. Alzheimers Dis.9(4), 421–427 (2006).
   PubMedGoogle Scholar
• Zhao WQ, Latinwo L, Liu XX, Lee ES, Lamango N, Charlton CG. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase. Exp. Neurol.171(1), 127–138 (2001).
   PubMed Web of Science ®Google Scholar
• Muhlack S, Woitalla D, Welnic J, Twiehaus S, Przuntek H, Müller T. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson’s disease. Neurosci. Lett.363(3), 284–287 (2004).
   PubMed Web of Science ®Google Scholar
• Müller T, Woitalla D, Saft C, Kuhn W. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat. Disord.6(3), 171–173 (2000).
   PubMed Web of Science ®Google Scholar
• Woitalla D, Goetze O, Kim JI et al. Levodopa availability improves with progression of Parkinson’s disease. J. Neurol.253(9), 1221–1226 (2006).
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Iliceto G, deMari M, Livrea P, Lamberti P. Management of L-dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review. Clin. Chem. Lab. Med.45(12), 1607–1613 (2007).
   PubMedGoogle Scholar
• Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Müller T. Hyperhomocysteinaemia in Parkinson’s disease. J. Neurol.245(12), 811–812 (1998).
   PubMed Web of Science ®Google Scholar
• Kuhn W, Roebroek R, Blom H et al. Elevated plasma levels of homocysteine in Parkinson’s disease. Eur. Neurol.40(4), 225–227 (1998).
   PubMed Web of Science ®Google Scholar
• Blandini F, Fancellu R, Martignoni E et al. Plasma homocysteine and L-dopa metabolism in patients with Parkinson disease. Clin. Chem.47(6), 1102–1104 (2001).
   PubMed Web of Science ®Google Scholar
• Brattstrom L. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology56(2), 281–282 (2001).
   PubMedGoogle Scholar
• Caccamo D, Gorgone G, Curro M et al. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neuromolecular Med.9(3), 249–254 (2007).
   PubMedGoogle Scholar
• Di RA, Werner P. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology62(4), 676–677 (2004).
   Google Scholar
• Hassin-Baer S, Cohen O, Vakil E et al. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin. Neuropharmacol.29(6), 305–311 (2006).
   PubMed Web of Science ®Google Scholar
• Lamberti P, Zoccolella S, Iliceto G et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson’s disease patients. Mov. Disord.20(1), 69–72 (2005).
   PubMed Web of Science ®Google Scholar
• Müller T, Woitalla D, Fowler B, Kuhn W. 3-OMD and homocysteine plasma levels in parkinsonian patients. J. Neural Transm.109(2), 175–179 (2002).
   PubMed Web of Science ®Google Scholar
• Müller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson’s disease. Neurosci. Lett.308(1), 54–56 (2001).
   PubMed Web of Science ®Google Scholar
• Müller T, Kuhn W. Neurotoxicity of levodopa: treatment-associated homocysteine increase. Nat. Clin. Pract. Neurol.3(6), E1 (2007).
   PubMedGoogle Scholar
• O’Suilleabhain PE, Sung V, Hernandez C et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch. Neurol.61(6), 865–868 (2004).
   PubMed Web of Science ®Google Scholar
• O’Suilleabhain PE, Bottiglieri T, Dewey RB Jr, Sharma S, az-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson’s disease. Mov Disord.19(12), 1403–1408 (2004).
   PubMed Web of Science ®Google Scholar
• Ozer F, Meral H, Hanoglu L et al. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol. Res.28(8), 853–858 (2006).
   PubMed Web of Science ®Google Scholar
• Schroecksnadel K, Leblhuber F, Fuchs D. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology62(4), 676–677 (2004).
   PubMedGoogle Scholar
• Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson’s disease. Acta Neurol. Scand.108(1), 66–67 (2003).
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin. Neuropharmacol.29(3), 106–111 (2006).
   PubMed Web of Science ®Google Scholar
• Lamberti P, Zoccolella S, Armenise E et al. Hyperhomocysteinemia in L-dopa treated Parkinson’s disease patients: effect of cobalamin and folate administration. Eur. J. Neurol.12(5), 365–368 (2005).
   PubMed Web of Science ®Google Scholar
• Liu XX, Wilson K, Charlton CG. Effects of L-dopa treatment on methylation in mouse brain: implications for the side effects of L-dopa. Life Sci.66(23), 2277–2288 (2000).
   PubMedGoogle Scholar
• Faucheux BA, Bonnet AM, Agid Y, Hirsch EC. Blood vessels change in the mesencephalon of patients with Parkinson’s disease. Lancet353(9157), 981–982 (1999).
   PubMed Web of Science ®Google Scholar
• Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C, Blandini F. Homocysteine and Parkinson’s disease: a dangerous liaison? J. Neurol. Sci.257(1–2), 31–37 (2007).
   PubMed Web of Science ®Google Scholar
• Siniscalchi A, Gallelli L, Mercuri NB, Ibbadu GF, De Sarro G. Role of lifestyle factors on plasma homocysteine levels in Parkinson’s disease patients treated with levodopa. Nutr. Neurosci.9(1–2), 11–16 (2006).
   PubMed Web of Science ®Google Scholar
• Todorovic Z, Dzoljic E, Novakovic I et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson’s disease, with and without levodopa therapy. J. Neurol. Sci.248(1–2), 56–61 (2006).
   PubMed Web of Science ®Google Scholar
• Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology55(3), 437–440 (2000).
   PubMed Web of Science ®Google Scholar
• Ben Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J. Neurol. Neurosurg. Psychiatry58(3), 293–299 (1995).
   PubMed Web of Science ®Google Scholar
• Gorell JM, Johnson CC, Rybicki BA. Parkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology44(10), 1865–1868 (1994).
   PubMed Web of Science ®Google Scholar
• Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s Disease Research Group of the United Kingdom. Br. Med. J.311(7020), 1602–1607 (1995).
   PubMed Web of Science ®Google Scholar
• Przuntek H, Welzel D, Blumner E et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur. J. Clin. Pharmacol.43(4), 357–363 (1992).
   PubMedGoogle Scholar
• Rinne UK. [Combination therapy with lisuride and L-dopa in the early stages of Parkinson’s disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy]. Nervenarzt70(Suppl. 1), S19–S25 (1999).
   Google Scholar
• Hely MA, Morris JG, Traficante R, Reid WG, O’Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J. Neurol. Neurosurg. Psychiatry67(3), 300–307 (1999).
   PubMed Web of Science ®Google Scholar
• Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord.20(2), 190–199 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao WQ, Williams Z, Shepherd KR et al. S-adenosyl-methionine-induced apoptosis in PC12 cells. J. Neurosci. Res.69(4), 519–529 (2002).
   PubMedGoogle Scholar
• Müller T, Fowler B, Kuhn W. Levodopa intake increases plasma levels of S-adenosylmethionine in treated patients with Parkinson disease. Clin. Neuropharmacol.28(6), 274–276 (2005).
   PubMedGoogle Scholar
• Charlton CG, Crowell B Jr. Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S-adenosylmethionine: a possible role of hypermethylation in parkinsonism. Mol. Chem. Neuropathol.26(3), 269–284 (1995).
   PubMedGoogle Scholar
• Charlton CG. Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosylmethionine: a model that may explain the occurrence of depression in Parkinson’s disease. Life Sci.61(5), 495–502 (1997).
   PubMedGoogle Scholar
• Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs48(2), 137–152 (1994).
   PubMed Web of Science ®Google Scholar
• Williams AC, Ramsden DB. Autotoxicity, methylation and a road to the prevention of Parkinson’s disease. J. Clin. Neurosci.12(1), 6–11 (2005).
   PubMed Web of Science ®Google Scholar
• Witjas T, Kaphan E, Azulay JP et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology59(3), 408–413 (2002).
   PubMed Web of Science ®Google Scholar
• Matsubara K, Aoyama K, Suno M, Awaya T. N-methylation underlying Parkinson’s disease. Neurotoxicol. Teratol.24(5), 593–598 (2002).
   PubMed Web of Science ®Google Scholar
• Rogers JD, Sanchez-Saffon A, Frol AB, az-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch. Neurol.60(1), 59–64 (2003).
   PubMed Web of Science ®Google Scholar
• Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology63(5), 886–891 (2004).
   PubMed Web of Science ®Google Scholar
• Reutens S, Sachdev P. Homocysteine in neuropsychiatric disorders of the elderly. Int. J. Geriatr. Psychiatry17(9), 859–864 (2002).
   PubMedGoogle Scholar
• Taly AB, Muthane UB. Involvement of peripheral nervous system in juvenile Parkinson’s disease. Acta Neurol. Scand.85(4), 272–275 (1992).
   PubMed Web of Science ®Google Scholar
• Okuma Y, Hattori N, Mizuno Y. Sensory neuropathy in autosomal recessive juvenile parkinsonism (PARK2). Parkinsonism Relat. Disord.9(5), 313–314 (2003).
   PubMedGoogle Scholar
• Müller T. Dopaminergic substitution in Parkinson’s disease. Expert Opin. Pharmacother.3(10), 1393–1403 (2002).
   PubMedGoogle Scholar
• Sachdev PS, Valenzuela M, Wang XL, Looi JC, Brodaty H. Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology58(10), 1539–1541 (2002).
   PubMed Web of Science ®Google Scholar
• Lee ES, Chen H, Soliman KF, Charlton CG. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology26(3), 361–371 (2005).
   PubMed Web of Science ®Google Scholar
• Tissingh G, Berendse HW, Bergmans P et al. Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov. Disord.16(1), 41–46 (2001).
   PubMed Web of Science ®Google Scholar
• Müller A, Mungersdorf M, Reichmann H, Strehle G, Hummel T. Olfactory function in parkinsonian syndromes. J. Clin. Neurosci.9(5), 521–524 (2002).
   PubMed Web of Science ®Google Scholar
• Sommer U, Hummel T, Cormann K et al. Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov. Disord.19(10), 1196–1202 (2004).
   PubMed Web of Science ®Google Scholar
• Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J. Neurochem.80(1), 101–110 (2002).
   PubMed Web of Science ®Google Scholar
• Mattson MP. Will caloric restriction and folate protect against AD and PD? Neurology60(4), 690–695 (2003).
   PubMed Web of Science ®Google Scholar
• Müller T, Woitalla D, Kuhn W. Benefit of folic acid supplementation in parkinsonian patients treated with levodopa. J. Neurol. Neurosurg. Psychiatry74(4), 549 (2003).
   PubMed Web of Science ®Google Scholar
• Ostrem JL, Kang GA, Subramanian I et al. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology64(8), 1482 (2005).
   PubMed Web of Science ®Google Scholar
• Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat. Disord.11(4), 253–256 (2005).
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Lamberti P, Armenise E et al. Plasma homocysteine levels in Parkinson’s disease: role of antiparkinsonian medications. Parkinsonism Relat. Disord.11(2), 131–133 (2005).
   PubMed Web of Science ®Google Scholar
• Müller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch. Neurol.61(5), 657–660 (2004).
   PubMed Web of Science ®Google Scholar
• Heider I, Lehmensiek V, Lenk T, Müller T, Storch A. Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures. J. Neural Transm. Suppl. (68), 1–13 (2004).
   PubMedGoogle Scholar
• Storch A, Blessing H, Bareiss M et al. Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons. Mol. Pharmacol.57(3), 589–594 (2000).
   PubMedGoogle Scholar
• Naoi M, Maruyama W, Nakao N, Ibi T, Sahashi K, Benedetti MS. (R)salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes. Ann. Neurol.43(2), 212–216 (1998).
   PubMed Web of Science ®Google Scholar
• Aoyama K, Matsubara K, Okada K et al.N-methylation ability for azaheterocyclic amines is higher in Parkinson’s disease: nicotinamide loading test. J. Neural Transm.107(8–9), 985–995 (2000).
   PubMed Web of Science ®Google Scholar
• Aoyama K, Matsubara K, Kondo M et al. Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson’s disease. Neurosci. Lett.298(1), 78–80 (2001).
   PubMedGoogle Scholar
• Müller T, Sallstrom BS, Haussermann P et al. Plasma levels of R- and S-salsolinol are not increased in “de-novo” Parkinsonian patients. J. Neural Transm.105(2–3), 239–246 (1998).
   PubMedGoogle Scholar
• Müller T, Sallstrom BS, Haussermann P, Przuntek H, Rommelspacher H, Kuhn W. R- and S-salsolinol are not increased in cerebrospinal fluid of Parkinsonian patients. J. Neurol. Sci.164(2), 158–162 (1999).
   PubMedGoogle Scholar
• Kuhn W, Woitalla D, Gerlach M, Russ H, Müller T. Tolcapone and neurotoxicity in Parkinson’s disease. Lancet352(9136), 1313–1314 (1998).
   PubMedGoogle Scholar
• Fuso A, Seminara L, Cavallaro RA, D’Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and β-amyloid production. Mol. Cell. Neurosci.28(1), 195–204 (2005).
   PubMed Web of Science ®Google Scholar
• Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson’s disease. Neurosci. Res.29(2), 99–111 (1997).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch. Neurol.53(6), 538–542 (1996).
   PubMedGoogle Scholar
• Agnati LF, Genedani S, Rasio G et al. Studies on homocysteine plasma levels in Alzheimer’s patients. Relevance for neurodegeneration. J. Neural Transm.112(1), 163–169 (2005).
   PubMed Web of Science ®Google Scholar
• Andrich J, Saft C, Arz A et al. Hyperhomocysteinaemia in treated patients with Huntington’s disease homocysteine in HD. Mov. Disord.19(2), 226–228 (2004).
   PubMed Web of Science ®Google Scholar
• Isobe C, Murata T, Sato C, Terayama Y. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer’s disease and Parkinson’s disease. Life Sci.77(15), 1836–1843 (2005).
   PubMed Web of Science ®Google Scholar
• Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology58(10), 1471–1475 (2002).
   PubMed Web of Science ®Google Scholar
• Cravo ML, Camilo ME. Hyperhomocysteinemia in chronic alcoholism: relations to folic acid and vitamins B(6) and B(12) status. Nutrition16(4), 296–302 (2000).
   PubMed Web of Science ®Google Scholar
• Miller JW. Homocysteine, Alzheimer’s disease, and cognitive function. Nutrition16(7–8), 675–677 (2000).
   PubMed Web of Science ®Google Scholar
• Almeida OP, Lautenschlager N, Flicker L et al. Association between homocysteine, depression, and cognitive function in community-dwelling older women from Australia. J. Am. Geriatr. Soc.52(2), 327–328 (2004).
   PubMed Web of Science ®Google Scholar
• Andres E, Perrin AE, Demangeat C et al. The syndrome of food-cobalamin malabsorption revisited in a department of internal medicine. A monocentric cohort study of 80 patients. Eur. J. Intern. Med.14(4), 221–226 (2003).
   PubMedGoogle Scholar
• Elias MF, Robbins MA, Budge MM et al. Homocysteine, folate, and vitamins B6 and B12 blood levels in relation to cognitive performance: the Maine–Syracuse study. Psychosom. Med.68(4), 547–554 (2006).
   PubMed Web of Science ®Google Scholar